Martien van Wenum
Overview
Explore the profile of Martien van Wenum including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
756
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Wenum M, Treskes P, Adam A, van der Mark V, Jongejan A, Moerland P, et al.
Cell Physiol Biochem
. 2018 Aug;
48(5):2189-2204.
PMID: 30110678
Background/aims: For applicability of cell-based therapies aimed at the treatment of liver failure, such as bioartificial livers (BALs) and hepatocyte transplantation, it is essential that the applied hepatocytes tolerate exposure...
2.
van Wenum M, Adam A, van der Mark V, Chang J, Wildenberg M, Hendriks E, et al.
J Cell Commun Signal
. 2018 Feb;
12(3):575-588.
PMID: 29399736
The in vitro generation of terminally differentiated hepatocytes is an unmet need. We investigated the contribution of oxygen concentration to differentiation in human liver cell lines HepaRG and C3A. HepaRG...
3.
Adam A, van Wenum M, van der Mark V, Jongejan A, Moerland P, Houtkooper R, et al.
Mitochondrion
. 2017 Aug;
39:30-42.
PMID: 28844938
Background: Human liver cell lines, like HepaRG and C3A, acquire higher functionality when cultured in the AMC-Bio-Artificial Liver (AMC-BAL). The three main differences between BAL and monolayer culture are the...
4.
van Wenum M, Treskes P, Tang C, Coppens E, Jansen K, Hendriks E, et al.
Biofabrication
. 2017 Jul;
9(3):035001.
PMID: 28664876
A new generation of bioartificial livers, based on differentiated proliferative hepatocyte sources, has been developed. Several practicable and regulatory demands have to be addressed before these can be clinically evaluated....
5.
van Wenum M, Adam A, Hakvoort T, Hendriks E, Shevchenko V, van Gulik T, et al.
Int J Biol Sci
. 2016 Aug;
12(8):964-78.
PMID: 27489500
Recently, the first clinical trials on Bioartificial Livers (BALs) loaded with a proliferative human hepatocyte cell source have started. There are two cell lines that are currently in an advanced...
6.
Huch M, Gehart H, van Boxtel R, Hamer K, Blokzijl F, Verstegen M, et al.
Cell
. 2014 Dec;
160(1-2):299-312.
PMID: 25533785
Despite the enormous replication potential of the human liver, there are currently no culture systems available that sustain hepatocyte replication and/or function in vitro. We have shown previously that single...
7.
van Wenum M, Chamuleau R, van Gulik T, Siliakus A, Seppen J, Hoekstra R
Expert Opin Biol Ther
. 2014 Nov;
14(12):1745-60.
PMID: 25366164
Introduction: Bioartificial livers (BALs) were originally developed to treat patients suffering from severe liver failure and relied on primary hepatocytes or on hepatoblastoma-derived cell lines. Currently, new in vitro BAL...